公开(公告)号：US09759726B2

公开(公告)日：2017-09-12

申请号：US14698660

申请日：2015-04-28

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Jim-Min Fang ,  Jiun-Jie Shie

IPC: C07D309/14 ,  G01N33/58 ,  C07K7/08 ,  G01N21/64 ,  C07D311/02 ,  C07F5/02

CPC classification number: G01N33/582 ,  C07D309/14 ,  C07D311/02 ,  C07F5/027 ,  C07K7/08 ,  G01N21/64 ,  G01N2333/924 ,  G01N2458/30

Abstract: Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.

公开(公告)号：US20150273034A1

公开(公告)日：2015-10-01

申请号：US14675838

申请日：2015-04-01

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Alice L. Yu ,  John Yu

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/55511 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  C12N15/1137 ,  C12N2310/14

Abstract: An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.

Abstract translation: 含有载体蛋白的聚糖缀合物和包含Globo H，其免疫原性片段或阶段特异性胚胎抗原-4（SSEA-4）的聚糖的免疫原性组合物，其中所述聚糖通过接头与载体蛋白缀合 。

公开(公告)号：US11918641B2

公开(公告)日：2024-03-05

申请号：US17998208

申请日：2021-05-07

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey Wong ,  Hsin-Yu Liao ,  Shih-Chi Wang ,  Yi-An Ko ,  Kuo-I Lin ,  Che Ma ,  Ting-Jen Cheng

IPC: A61K39/145 ,  A61K35/76 ,  A61K39/00 ,  A61K39/12 ,  A61P31/16 ,  C07K14/005 ,  C07K14/11

CPC classification number: A61K39/145 ,  A61P31/16 ,  C07K14/005 ,  A61K2039/575

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

公开(公告)号：US11884739B2

公开(公告)日：2024-01-30

申请号：US17211619

申请日：2021-03-24

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Ming-Hung Tsai

IPC: C07K16/28 ,  C12P21/00 ,  A61K39/00

CPC classification number: C07K16/2887 ,  C07K16/283 ,  C12P21/005 ,  C12Y302/01 ,  C12Y302/01051 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：US20200095233A1

公开(公告)日：2020-03-26

申请号：US16081490

申请日：2017-02-28

Applicant: Academia Sinica ,  National Taiwan University

Inventor： Chi-Huey Wong ,  Pan-Chyr Yang ,  Rong-Jie Chein ,  Szu-Hua Pan ,  Ting-Jen R. Cheng

IPC: C07D405/12 ,  C07D413/12 ,  C07D307/92 ,  C07D403/12

Abstract: The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

公开(公告)号：US20200046826A1

公开(公告)日：2020-02-13

申请号：US16431099

申请日：2019-06-04

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Che Ma ,  Cheng-Chi Wang ,  Juine-Ruey Chen

IPC: A61K39/145 ,  A61K39/12 ,  C07K16/10 ,  C12N7/00

Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

公开(公告)号：US10150818B2

公开(公告)日：2018-12-11

申请号：US14798312

申请日：2015-07-13

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Tsui-Ling Hsu ,  Yi-Wei Lou ,  Chih-Wei Lin ,  Shih-Chi Yeh ,  Chung-Yi Wu ,  Han-Chung Wu

IPC: C07K16/44 ,  G01N33/574 ,  C07K16/30 ,  C07K16/18 ,  A61K39/00

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：US10111951B2

公开(公告)日：2018-10-30

申请号：US15689165

申请日：2017-08-29

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Alice L. Yu ,  Kun-Hsien Lin ,  Tai-Na Wu

IPC: A61K39/39 ,  C07H15/18 ,  A61K39/00

Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

公开(公告)号：US10023892B2

公开(公告)日：2018-07-17

申请号：US14723297

申请日：2015-05-27

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Che Ma

IPC: C07K16/00 ,  C12P19/14 ,  A61K39/395 ,  A61K39/42 ,  A61K45/06 ,  C07K16/10 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N9/24 ,  C07K16/18 ,  A61K39/00

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

公开(公告)号：US09981030B2

公开(公告)日：2018-05-29

申请号：US14392333

申请日：2014-06-27

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Chia-Hung Wang ,  Shiou-Ting Li

IPC: A61K31/715 ,  C08B37/00 ,  A61K39/095 ,  C07H1/00 ,  C07H15/04 ,  C07H15/18 ,  A61K39/385 ,  A61K39/39 ,  A61K39/00

CPC classification number: A61K39/095 ,  A61K31/715 ,  A61K39/385 ,  A61K39/39 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55566 ,  A61K2039/55577 ,  A61K2039/6037 ,  A61K2039/627 ,  C07H1/00 ,  C07H15/04 ,  C07H15/18 ,  C08B37/006

Abstract: Described herein are synthetic glycan conjugates comprising a carrier and a glycan moiety derived from Neisseria meningitidis, wherein the glycan moiety is covalently linked to the carrier through a linker. Also provided herein are a mixture of the glycan conjugates thereof, immmunogenic compositions thereof, and kits thereof. The invention further provides methods of using the synthetic glycan conjugates and immunogenic compositions thereof to treat and/or reduce the risk of infectious diseases such as bacterial infections.